Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Priofect is a proprietary line of polyamidoamine (PAMAM) dendrimers developed by Starpharma, specifically engineered for the high-efficiency delivery of nucleic acids, including siRNA and DNA, as well as other therapeutic agents. These dendrimers are spherical, highly branched macromolecules with a well-defined three-dimensional structure that allows for the precise attachment or encapsulation of active pharmaceutical ingredients. Priofect functions as a transfection reagent and delivery scaffold, improving the stability, solubility, and cellular internalization of its cargo. While primarily utilized as a transfection reagent in research and diagnostic settings, the Priofect technology represents a significant application of dendrimer technology in the development of targeted therapeutic interventions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Priofect.